

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



01 September 2026

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Enclosed herewith is a copy of the press release titled “Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments,” which shall be released after this intimation.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



FOR IMMEDIATE RELEASE

Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments

MUMBAI, INDIA and PRINCETON, NJ, September 01, 2026 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, together with its subsidiaries and/or affiliated companies, “Sun Pharma”) today joined several pharmaceutical companies at a White House ceremony to announce agreements with the U.S. government aimed at prioritizing access to affordable medicines for millions of American patients.

As part of its agreement, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programs. Sun Pharma also commits to MFN pricing for future innovative medicine launches. The agreement recognizes Sun Pharma’s investment in the U.S. market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years. Further terms of the agreements remain confidential.

“Our mission is to reach people and touch lives by providing quality medicines across a patient’s entire treatment journey, from consumer health products to generics to innovative medicines,” said Rick Ascroft, North America CEO, Sun Pharma, who represented the company at the White House. “The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing. We are proud to play our part in delivering the medicines that millions of American patients count on every day.”

Sun Pharma initially built its U.S. presence on a foundation of high-quality generics followed by an increasing emphasis on innovative and specialty medicines. The company ranks second by prescriptions in U.S. dermatology and continues to expand across dermatology and immunology, cutaneous oncology, and ophthalmology, complementing a robust consumer health products and generics business.

The U.S. is Sun Pharma’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue. Commitment to the U.S. market was further underscored earlier this year through Sun Pharma’s definitive agreement to acquire Organon & Co. at an enterprise value of \$11.75 billion - a milestone that reflects Sun Pharma’s continued investment in American patients, healthcare providers, and communities.

Sun Pharma remains focused on its core mission of expanding access to high-quality, affordable medicines for patients in the U.S. and around the world.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is a leading global pharmaceutical company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 22% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations.

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



For further information, please visit www.sunpharma.com and follow us on [LinkedIn](#) & [X](#) (formerly Twitter).

Contacts: Sun Pharma

Investors

Dr. Abhishek Sharma
Tel: +91 22 4324 4324, Ext 2929
Tel Direct: +91 22 4324 2929
Mobile: +91 98196 86016
Email: abhi.sharma@sunpharma.com

Media

Gaurav Chugh
Tel: +91 22 4324 4324, Ext 5373
Tel Direct: +91 22 4324 5373
Mobile: +91 98104 71414
Email: gaurav.chugh@sunpharma.com

U.S. Media Contact

Rob Perry
Head of North America Corporate Communications
Email: robert.perry@sunpharma.com